Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methamphetamine | 1 | 2021 | 32 | 0.740 |
Why?
|
| Designer Drugs | 1 | 2015 | 4 | 0.500 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2015 | 141 | 0.460 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 122 | 0.460 |
Why?
|
| Breast Neoplasms | 4 | 2025 | 2512 | 0.400 |
Why?
|
| Piperazines | 2 | 2025 | 240 | 0.370 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 459 | 0.360 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 686 | 0.320 |
Why?
|
| Neoadjuvant Therapy | 2 | 2008 | 341 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1254 | 0.230 |
Why?
|
| Pyridines | 1 | 2025 | 230 | 0.210 |
Why?
|
| Craving | 1 | 2021 | 14 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 1142 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2012 | 1506 | 0.130 |
Why?
|
| Short Bowel Syndrome | 1 | 2016 | 65 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 1694 | 0.120 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1276 | 0.120 |
Why?
|
| Enteral Nutrition | 1 | 2016 | 257 | 0.110 |
Why?
|
| Peptides | 1 | 2016 | 811 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 151 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 418 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 306 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 6604 | 0.070 |
Why?
|
| Receptors, CXCR4 | 1 | 2008 | 56 | 0.070 |
Why?
|
| Survival Rate | 1 | 2012 | 2064 | 0.070 |
Why?
|
| Humans | 7 | 2025 | 125195 | 0.060 |
Why?
|
| Aged | 3 | 2025 | 19881 | 0.060 |
Why?
|
| Carcinoma | 1 | 2008 | 287 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1241 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 2 | 2025 | 515 | 0.060 |
Why?
|
| Mastectomy | 1 | 2005 | 64 | 0.060 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 795 | 0.060 |
Why?
|
| Middle Aged | 4 | 2025 | 26938 | 0.060 |
Why?
|
| Age Factors | 2 | 2016 | 2823 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 144 | 0.060 |
Why?
|
| Receptors, Progesterone | 2 | 2025 | 878 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 320 | 0.060 |
Why?
|
| Aromatase Inhibitors | 1 | 2025 | 76 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12396 | 0.060 |
Why?
|
| Adult | 4 | 2025 | 29639 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 363 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2106 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 668 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 898 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5176 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2016 | 3465 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2025 | 1056 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2025 | 16344 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 1893 | 0.040 |
Why?
|
| Female | 5 | 2025 | 66803 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2025 | 1179 | 0.040 |
Why?
|
| Prognosis | 2 | 2008 | 4641 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 2174 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 729 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1696 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1288 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 6159 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 401 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 2913 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2008 | 290 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 756 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 417 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 2064 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 14022 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 19355 | 0.010 |
Why?
|
| Child | 1 | 2016 | 24407 | 0.010 |
Why?
|
| Male | 1 | 2016 | 61524 | 0.010 |
Why?
|